Polypid’s SHIELD II Trial Delivers Transformative Results
PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial of D-PLEX100, demonstrating a statistically significant...
Polypid Shield’s Phase 3 Results: Paradigm Shift in Surgical Infection Prevention
PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial, showing D-PLEX100 significantly reduced surgical site...
Unprecedented 76-Week Barzolvolimab Results in Chronic Urticaria
Celldex released 76-week data from a Phase 2 trial of barzolvolimab for chronic spontaneous urticaria (CSU). Seven months after...
Revumenib Data from BEAT AML Trial Published in JCO & Presented at EHA 2025
Syndax Pharmaceuticals announced positive results from the BEAT AML trial of revumenib combined with venetoclax and azacitidine (ven/aza) in...
Apex Labs Expands Macrodose Psilocybin PTSD Trial
Apex Labs Ltd. received approval from Israel’s Ministry of Health to expand its phase 2b clinical trial, SUMMIT-90, for...
Neurostimulation Trial for Opioid Disorder Shows Promising Results
Spark Biomedical concluded enrollment for its pivotal clinical trial using transcutaneous auricular neurostimulation (tAN) to improve treatment retention for...
One Medicine, One Platform: How Boehringer Ingelheim Is Redefining Pharma Transformation
At the 2025 Veeva R&D and Quality Summit Europe, Martin Helling, Executive Director of the One Medicine Platform at...
AI’s Transformative Role in Clinical Trials: Insights from Lokavant’s CEO
Artificial intelligence (AI) is reshaping clinical trials, offering new efficiencies and insights. Rohit Nambisan, CEO of Lokavant, shares his...
Atai & Beckley Psychedelic Merger Creates Global Mental Health Leader
Atai Life Sciences and Beckley Psytech are merging in an all-stock transaction, creating atai Beckley, a leading mental health...
Promising Data: Alrizomadlin in Solid Tumors
Ascentage Pharma released Phase II clinical trial data for its MDM2-p53 inhibitor, alrizomadlin (APG-115), at the 2025 ASCO Annual...